Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
Public ClinicalTrials.gov record NCT03600649. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) With and Without Topotecan and Cyclophosphamide in Patients With Relapsed or Refractory Ewing Sarcoma and Select Sarcomas
Study identification
- NCT ID
- NCT03600649
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Salarius Pharmaceuticals, LLC
- Industry
- Enrollment
- 50 participants
Conditions and interventions
Conditions
Interventions
- Cyclophosphamide Drug
- Seclidemstat Drug
- Topotecan Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 3, 2018
- Primary completion
- Aug 31, 2025
- Completion
- Nov 30, 2025
- Last update posted
- Nov 20, 2023
2018 – 2025
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Children's Hospital Los Angeles | Los Angeles | California | 90027 | — |
| Sarcoma Oncology Research Center | Santa Monica | California | 90403 | — |
| Mayo Clinic | Jacksonville | Florida | 32224 | — |
| Johns Hopkins All Children's Hospital | St. Petersburg | Florida | 33701 | — |
| H. Lee Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Cleveland Clinic Taussig Cancer Institute | Cleveland | Ohio | 44195 | — |
| The Research Institute at Nationwide Children's Hospital | Columbus | Ohio | 43205 | — |
| Oregon Health Sciences University | Portland | Oregon | 97239 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 77030 | — |
| University of Washington | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03600649, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 20, 2023 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03600649 live on ClinicalTrials.gov.